vs
华美银行集团（EWBC）与GENMAB A/S（GMAB）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是华美银行集团的1.2倍（$925.0M vs $775.0M），华美银行集团净利率更高（46.2% vs 36.3%，领先9.9%），GENMAB A/S同比增速更快（18.7% vs 2.1%）
华美银行集团旗下核心子公司为华美银行，是总部位于美国南加州的最大上市银行控股集团。集团资产规模超100亿美元，曾获评标普全球市场财智全美最佳银行，自2023年起连续三年位列《银行董事》杂志同资产规模银行绩效榜单首位。
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
EWBC vs GMAB — 直观对比
营收规模更大
GMAB
是对方的1.2倍
$775.0M
营收增速更快
GMAB
高出16.6%
2.1%
净利率更高
EWBC
高出9.9%
36.3%
损益表 — Q1 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $775.0M | $925.0M |
| 净利润 | $358.0M | $336.0M |
| 毛利率 | — | 93.8% |
| 营业利润率 | — | 38.9% |
| 净利率 | 46.2% | 36.3% |
| 营收同比 | 2.1% | 18.7% |
| 净利润同比 | 0.4% | 65.5% |
| 每股收益（稀释后） | $2.57 | $5.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWBCGMAB
| Q1 26 | $775.0M | — | ||
| Q4 25 | $657.8M | — | ||
| Q3 25 | $677.5M | — | ||
| Q2 25 | $617.1M | $925.0M | ||
| Q1 25 | $600.2M | — | ||
| Q4 24 | $587.6M | — | ||
| Q3 24 | $572.7M | — | ||
| Q2 24 | $553.2M | $779.0M |
净利润EWBCGMAB
| Q1 26 | $358.0M | — | ||
| Q4 25 | $356.3M | — | ||
| Q3 25 | $368.4M | — | ||
| Q2 25 | $310.3M | $336.0M | ||
| Q1 25 | $290.3M | — | ||
| Q4 24 | $293.1M | — | ||
| Q3 24 | $299.2M | — | ||
| Q2 24 | $288.2M | $203.0M |
毛利率EWBCGMAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 93.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 96.4% |
营业利润率EWBCGMAB
| Q1 26 | — | — | ||
| Q4 25 | 71.0% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 65.2% | 38.9% | ||
| Q1 25 | 65.2% | — | ||
| Q4 24 | 60.6% | — | ||
| Q3 24 | 68.0% | — | ||
| Q2 24 | 65.9% | 30.3% |
净利率EWBCGMAB
| Q1 26 | 46.2% | — | ||
| Q4 25 | 54.2% | — | ||
| Q3 25 | 54.4% | — | ||
| Q2 25 | 50.3% | 36.3% | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 52.1% | 26.1% |
每股收益（稀释后）EWBCGMAB
| Q1 26 | $2.57 | — | ||
| Q4 25 | $2.55 | — | ||
| Q3 25 | $2.65 | — | ||
| Q2 25 | $2.24 | $5.42 | ||
| Q1 25 | $2.08 | — | ||
| Q4 24 | $2.10 | — | ||
| Q3 24 | $2.14 | — | ||
| Q2 24 | $2.06 | $3.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.0B | $5.3B |
| 总资产 | $82.9B | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EWBCGMAB
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | — | ||
| Q3 25 | $4.7B | — | ||
| Q2 25 | $4.4B | $1.3B | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $5.3B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $4.4B | $622.0M |
总债务EWBCGMAB
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | — | ||
| Q3 25 | $35.7M | — | ||
| Q2 25 | $35.8M | — | ||
| Q1 25 | $35.9M | — | ||
| Q4 24 | $36.0M | — | ||
| Q3 24 | $36.1M | — | ||
| Q2 24 | $36.1M | — |
股东权益EWBCGMAB
| Q1 26 | $9.0B | — | ||
| Q4 25 | $8.9B | — | ||
| Q3 25 | $8.6B | — | ||
| Q2 25 | $8.2B | $5.3B | ||
| Q1 25 | $7.9B | — | ||
| Q4 24 | $7.7B | — | ||
| Q3 24 | $7.7B | — | ||
| Q2 24 | $7.2B | $4.4B |
总资产EWBCGMAB
| Q1 26 | $82.9B | — | ||
| Q4 25 | $80.4B | — | ||
| Q3 25 | $79.7B | — | ||
| Q2 25 | $78.2B | $6.5B | ||
| Q1 25 | $76.2B | — | ||
| Q4 24 | $76.0B | — | ||
| Q3 24 | $74.5B | — | ||
| Q2 24 | $72.5B | $5.6B |
负债/权益比EWBCGMAB
| Q1 26 | — | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $349.0M |
| 自由现金流经营现金流 - 资本支出 | — | $327.0M |
| 自由现金流率自由现金流/营收 | — | 35.4% |
| 资本支出强度资本支出/营收 | — | 2.4% |
| 现金转化率经营现金流/净利润 | — | 1.04× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流EWBCGMAB
| Q1 26 | — | — | ||
| Q4 25 | $713.4M | — | ||
| Q3 25 | $231.7M | — | ||
| Q2 25 | $278.7M | $349.0M | ||
| Q1 25 | $277.9M | — | ||
| Q4 24 | $500.1M | — | ||
| Q3 24 | $386.1M | — | ||
| Q2 24 | $259.2M | $438.0M |
自由现金流EWBCGMAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $327.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $430.0M |
自由现金流率EWBCGMAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 35.4% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 55.2% |
资本支出强度EWBCGMAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.0% |
现金转化率EWBCGMAB
| Q1 26 | — | — | ||
| Q4 25 | 2.00× | — | ||
| Q3 25 | 0.63× | — | ||
| Q2 25 | 0.90× | 1.04× | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 1.71× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 0.90× | 2.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EWBC
暂无分部数据
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
